The screening approach we used here aims to identify stocks that combine strong earnings momentum with a well-defined technical breakout pattern. By requiring a ChartMill Setup Rating above 7 and a Technical Rating above 7, we filter for names that are both trending well and forming a consolidation zone near potential entry points. Adding a High Growth Momentum Rating above 4 ensures the underlying business is showing accelerating sales, earnings growth, earnings surprises, and positive analyst revisions—the kind of fundamental fuel that growth investors look for in a leader.
Travere Therapeutics (NASDAQ:TVTX) is a biopharmaceutical company focused on rare kidney and metabolic diseases, with approved and late-stage therapies including FILSPARI for IgA nephropathy and pegtibatinase for classical homocystinuria. The stock scores a High Growth Momentum Rating of 6 out of 10—a solid level that already indicates meaningful fundamental acceleration, and it also earns a perfect Technical Rating of 10 and a Setup Rating of 8, placing it in the top tier of breakout candidates.
Why Travere Therapeutics Fits the High Growth Momentum Criteria
The High Growth Momentum rating captures the short???term earnings and sales acceleration that growth investors prize. Travere’s latest reported TTM EPS growth of 91.8% and revenue growth of 96% already signal strong top??? and bottom???line expansion. Looking further into the quarterly progression, the most recent quarter’s EPS grew 14.9% year???over???year, while the prior quarter recorded a 104.1% jump and the quarter before that an even bigger 140% surge. This demonstrates the kind of acceleration the rating rewards.
Sales growth has been equally impressive: the last quarter’s year???over???year sales increase of 55.6% follows two quarters of 73.4% and 162.1% growth, respectively. Such sustained revenue acceleration is a hallmark of companies scaling quickly. The rating also factors in analyst revisions, and here Travere shows a 55.6% positive revision in next???year EPS estimates over the last three months, alongside three earnings beats out of the past four quarters, with an average beat magnitude of 90.8%. These elements together explain why the stock earns a High Growth Momentum Rating of 6.
Technical Strength and Breakout Setup
On the technical side, Travere’s perfect rating of 10 reflects a dominant uptrend. The stock is trading near its 52???week high, outperforming 98% of all stocks in the universe, and its long??? and short???term trends are both positive. The relative strength reading of 98.92 confirms it is a market leader relative to the broader market.
What makes it especially relevant for a breakout strategy is the Setup Rating of 8. The technical report notes that prices have been consolidating recently, forming a bull flag pattern after a strong upward move. A clear resistance zone exists just above the current price, starting at $58.86, and a support zone runs from $56.44 to $57.02. The report also highlights recent large???player accumulation via effective volume and a pocket pivot signal—both positive signs that institutional interest is building. A potential buy stop entry above $59.05 is suggested, with a stop loss around $56.43, offering a controlled risk???reward profile.
For a more detailed look at the technical indicators and the full analysis, you can view the complete technical analysis report.
Putting It All Together
Stocks that score well across all three dimensions—fundamental momentum, technical health, and setup quality—are rare. Travere Therapeutics demonstrates that it is possible for a mid??? to small???cap biotech to combine quickly improving earnings and sales with a textbook consolidation pattern near new highs. The combination of a High Growth Momentum Rating of 6, a Technical Rating of 10, and a Setup Rating of 8 makes it a candidate worth monitoring for those who follow growth???momentum strategies.
If you want to explore more stocks that meet these same criteria, the High Growth Momentum Breakout Setups screen can be run daily to find the latest names with strong fundamental momentum and a favourable technical setup.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Past performance and screening results are not guarantees of future results. Always conduct your own due diligence and consider your risk tolerance before making any trading decisions.
Read full article here »
View the Zacks #1 Rank List
Travere Therapeutics (NASDAQ:TVTX): High Growth Momentum Stock with Breakout Setup
The screening approach we used here aims to identify stocks that combine strong earnings momentum with a well-defined technical breakout pattern. By requiring a ChartMill Setup Rating above 7 and a Technical Rating above 7, we filter for names that are both trending well and forming a consolidation zone near potential entry points. Adding a High Growth Momentum Rating above 4 ensures the underlying business is showing accelerating sales, earnings growth, earnings surprises, and positive analyst revisions—the kind of fundamental fuel that growth investors look for in a leader.
Travere Therapeutics (NASDAQ:TVTX) is a biopharmaceutical company focused on rare kidney and metabolic diseases, with approved and late-stage therapies including FILSPARI for IgA nephropathy and pegtibatinase for classical homocystinuria. The stock scores a High Growth Momentum Rating of 6 out of 10—a solid level that already indicates meaningful fundamental acceleration, and it also earns a perfect Technical Rating of 10 and a Setup Rating of 8, placing it in the top tier of breakout candidates.
Why Travere Therapeutics Fits the High Growth Momentum Criteria
The High Growth Momentum rating captures the short???term earnings and sales acceleration that growth investors prize. Travere’s latest reported TTM EPS growth of 91.8% and revenue growth of 96% already signal strong top??? and bottom???line expansion. Looking further into the quarterly progression, the most recent quarter’s EPS grew 14.9% year???over???year, while the prior quarter recorded a 104.1% jump and the quarter before that an even bigger 140% surge. This demonstrates the kind of acceleration the rating rewards.
Sales growth has been equally impressive: the last quarter’s year???over???year sales increase of 55.6% follows two quarters of 73.4% and 162.1% growth, respectively. Such sustained revenue acceleration is a hallmark of companies scaling quickly. The rating also factors in analyst revisions, and here Travere shows a 55.6% positive revision in next???year EPS estimates over the last three months, alongside three earnings beats out of the past four quarters, with an average beat magnitude of 90.8%. These elements together explain why the stock earns a High Growth Momentum Rating of 6.
Technical Strength and Breakout Setup
On the technical side, Travere’s perfect rating of 10 reflects a dominant uptrend. The stock is trading near its 52???week high, outperforming 98% of all stocks in the universe, and its long??? and short???term trends are both positive. The relative strength reading of 98.92 confirms it is a market leader relative to the broader market.
What makes it especially relevant for a breakout strategy is the Setup Rating of 8. The technical report notes that prices have been consolidating recently, forming a bull flag pattern after a strong upward move. A clear resistance zone exists just above the current price, starting at $58.86, and a support zone runs from $56.44 to $57.02. The report also highlights recent large???player accumulation via effective volume and a pocket pivot signal—both positive signs that institutional interest is building. A potential buy stop entry above $59.05 is suggested, with a stop loss around $56.43, offering a controlled risk???reward profile.
For a more detailed look at the technical indicators and the full analysis, you can view the complete technical analysis report.
Putting It All Together
Stocks that score well across all three dimensions—fundamental momentum, technical health, and setup quality—are rare. Travere Therapeutics demonstrates that it is possible for a mid??? to small???cap biotech to combine quickly improving earnings and sales with a textbook consolidation pattern near new highs. The combination of a High Growth Momentum Rating of 6, a Technical Rating of 10, and a Setup Rating of 8 makes it a candidate worth monitoring for those who follow growth???momentum strategies.
If you want to explore more stocks that meet these same criteria, the High Growth Momentum Breakout Setups screen can be run daily to find the latest names with strong fundamental momentum and a favourable technical setup.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Past performance and screening results are not guarantees of future results. Always conduct your own due diligence and consider your risk tolerance before making any trading decisions.
Read full article here »